GLP-1 drugs, originally developed to treat diabetes and obesity, are now showing significant benefits against at least ten different diseases, with FDA approvals expanding far beyond weight management. Recent clinical trials and real-world studies reveal that medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) work through multiple biological pathways that address inflammation, organ damage, and neurological function in ways researchers are still uncovering .

Which Diseases Are GLP-1 Drugs Now Approved to Treat?

The FDA has granted approvals for GLP-1 medications to treat a growing list of serious health conditions beyond their original diabetes and obesity indications. In January 2025, the FDA approved semaglutide for chronic kidney disease after a landmark study of over 3,500 patients showed it reduced serious kidney events to 5.8 per 100 patients per year, compared with 7.5 in the placebo group. Notably, these kidney improvements were not linked to weight loss, suggesting the drug works through direct protective mechanisms .

Cardiovascular protection emerged as another major benefit. Semaglutide reduced the risk of heart attack, stroke, and cardiovascular death by approximately 20 percent in a study published in the New England Journal of Medicine, leading to FDA approval for cardiovascular disease in people who are overweight or obese in March 2024. Over a follow-up period of roughly 40 months, 6.5 percent of patients taking semaglutide experienced serious cardiovascular events, compared with 8.0 percent in the placebo group .

Liver disease represents another area where these drugs are making an impact. In August 2025, the FDA granted accelerated approval for semaglutide for metabolic liver disease, based on a study showing that 62.9 percent of patients receiving semaglutide had improved liver inflammation without increased scarring, compared with 34.3 percent in the placebo group. A separate study involving HIV patients showed that liver fat decreased by 31 percent after six months of semaglutide treatment .

Sleep apnea became the first condition where tirzepatide earned FDA approval as the primary treatment. Zepbound received approval in December 2024 for moderate to severe obstructive sleep apnea after clinical trials showed tirzepatide reduced breathing interruptions during sleep by 25 to 29 per hour, compared with 5 to 6 in the placebo group .

What Emerging Benefits Are Researchers Investigating?

Beyond FDA-approved uses, researchers are exploring GLP-1 effects in several other conditions with promising early results. A large study of over 600,000 American veterans with type 2 diabetes found that GLP-1 use was linked to a 14 percent lower risk of developing substance use disorders. Among veterans with preexisting substance use disorders, GLP-1 use was associated with fewer drug-related emergency visits, hospitalizations, overdoses, and deaths over three years. A more recent study published in JAMA Psychiatry from February 2025 confirmed that patients with alcohol use disorder drank less and had fewer cravings for alcohol and cigarettes during treatment with semaglutide .

Joint and bone health is another emerging area. A study published in October 2024 in the New England Journal of Medicine showed that patients with obesity and knee osteoarthritis reported a 41.7 percent reduction in knee pain with semaglutide, compared with 27.5 percent with placebo. Researchers are still determining whether this effect results from weight loss alone or whether the drugs have specific anti-inflammatory actions on the joints themselves .

Cancer risk reduction has also caught researchers' attention. A study published in JAMA Oncology in December 2024 examining 101.2 million patient records found that people with type 2 diabetes who took GLP-1 drugs had a markedly reduced risk of colon cancer. Laboratory experiments show that GLP-1 drugs can reduce cancer cell migration and tumor growth. A review published in Nature Cancer in January listed dozens of ongoing clinical trials of GLP-1 drugs related to cancer, with a focus on endometrial, breast, and prostate cancer .

Respiratory health is showing improvement as well. A British study published in April 2025 examining approximately 60,000 patients found that those with obesity and asthma who took GLP-1 drugs had better control of their asthma symptoms. Researchers believe the drugs' anti-inflammatory effects may be behind these improvements .

How Do These Medications Work Across Multiple Diseases?

The mechanism behind GLP-1 drugs' broad effects lies in how they interact with the body's hormonal and neurological systems. Ozempic and Wegovy contain semaglutide, a synthetic version of the hormone GLP-1 that regulates blood sugar and signals fullness. Mounjaro and Zepbound contain tirzepatide, which mimics GLP-1 but also acts on a second hormonal pathway called GIP (glucose-dependent insulinotropic polypeptide). This dual action may explain why tirzepatide sometimes shows stronger effects than semaglutide alone .

"Patients with rheumatoid arthritis experiencing strong anti-inflammatory effects without losing weight," noted Daniel Drucker, an endocrinologist at the University of Toronto who has studied GLP-1 drugs for decades.

Daniel Drucker, Endocrinologist at the University of Toronto

Beyond inflammation, these drugs appear to work through multiple pathways simultaneously. Harlan Krumholz, professor of medicine at Yale University, has noted improvements in blood pressure among patients taking GLP-1 medications. Other clinicians have observed positive results in sleep apnea, joint pain, and liver disease, suggesting the drugs' benefits extend well beyond their primary mechanism of appetite suppression .

Steps to Understanding GLP-1 Benefits Beyond Weight Loss

• Recognize FDA-Approved Uses: GLP-1 drugs now have official FDA approval for kidney disease, heart disease, liver disease, and sleep apnea in addition to diabetes and obesity, meaning these are established medical treatments, not off-label experiments.
• Understand the Anti-Inflammatory Mechanism: Many benefits appear to stem from the drugs' ability to reduce inflammation throughout the body, which explains why they help conditions ranging from joint pain to asthma to liver disease.
• Know the Difference Between Weight Loss and Direct Effects: Some benefits, like kidney protection and cardiovascular improvement, occur independently of weight loss, indicating the drugs have direct protective effects on organs and tissues.
• Stay Informed About Ongoing Research: Dozens of clinical trials are underway examining GLP-1 effects on cancer, dementia, and other conditions, so the list of approved uses will likely expand in coming years.

The expanding use of GLP-1 medications reflects a fundamental shift in how doctors view these drugs. What began as a treatment for blood sugar control has evolved into a multi-system therapeutic tool. Eli Lilly, the manufacturer of tirzepatide, is now investing in inflammatory diseases such as Crohn's disease and severe skin and lung disorders, signaling that pharmaceutical companies see potential far beyond the original weight loss indication .

For women specifically, emerging research suggests additional benefits. Low doses of semaglutide reduced body weight in nearly 80 percent of patients with polycystic ovary syndrome (PCOS) who had not responded to previous treatment, and menstrual cycles normalized in these patients. There are also signs that weight loss linked to semaglutide may increase sperm count and sperm motility in men, while in women with type 2 diabetes, hormonal imbalances affecting ovulation may improve. At least a dozen studies are underway on GLP-1 use in PCOS and obesity .

The bottom line: GLP-1 drugs represent a rare example of a medication that works across multiple organ systems and disease states. While weight loss remains an important benefit for many patients, the emerging evidence suggests these medications offer protection and healing in ways that go far beyond the scale. As research continues, doctors and patients may find that GLP-1 drugs become standard treatment for conditions ranging from heart disease to kidney damage to substance use disorders, fundamentally changing how we approach chronic disease management.